Literature DB >> 15128882

Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury.

Luciano F Drager1, Lúcia Andrade, João Felipe Barros de Toledo, Francisco R M Laurindo, Luiz Antônio Machado César, Antonio Carlos Seguro.   

Abstract

BACKGROUND: N-Acetylcysteine has been shown to protect against contrast nephropathy, although the mechanisms underlying such an effect are unclear. Surprisingly, studies have shown that post-radiocontrast renal function actually improves in chronic renal failure patients receiving N-acetylcysteine. However, there have been no studies investigating the cause of this improvement.
METHODS: In a double-blind, placebo-controlled study, 24 patients (aged 65+/-2 years) suffering from stable mild-to-moderate renal insufficiency and undergoing elective coronary angiography were randomized to receive either placebo or N-acetylcysteine. All received similar hydration. Renal function parameters were assessed 48 h before and 48 h after radiocontrast administration. Urinary 15-isoprostane F2(t), a specific marker of oxidative stress, was measured immediately before and after the procedure. Expression of urinary alpha-glutathione S-transferase protein, a specific proximal tubular injury marker, was assessed after the procedure.
RESULTS: Comparing creatinine clearance values before and after angiography, a significant increase was seen in N-acetylcysteine patients (44.7+/-4.2 vs 57.2+/-6.3 ml/min/1.73 m(2); P = 0.02), whereas placebo patients presented no change (46.6+/-5.0 vs 46.9+/-4.3 ml/min/1.73 m(2); P = 0.90). After radiocontrast, urinary 15-isoprostane F2(t) levels in placebo patients increased significantly over baseline values (2.9+/-0.7 vs 10.3+/-2.1 ng/mg creatinine; P = 0.007), whereas urinary 15-isoprostane F2(t) levels in N-acetylcysteine patients remained basically unchanged (3.5+/-0.5 vs 4.1+/-0.9 ng/mg creatinine; P = 0.63). Furthermore, N-acetylcysteine treatment led to lower levels of alpha-glutathione S-transferase than did placebo treatment (0.8+/-0.2 vs 2.4+/-0.7 micro g/g; P = 0.046).
CONCLUSIONS: In chronic renal failure patients, the improvement in renal function induced by post-radiocontrast administration of N-acetylcysteine is strongly associated with suppression of oxidant stress-mediated proximal tubular injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128882     DOI: 10.1093/ndt/gfh261

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  32 in total

Review 1.  Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist.

Authors:  Jeffrey J Pasternak; Eric E Williamson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  Effects of a novel cystine-based glutathione precursor on oxidative stress in vascular smooth muscle cells.

Authors:  Indrani Sinha-Hikim; Ruoqing Shen; Wai-Nang N Paul Lee; Albert Crum; Nosratola D Vaziri; Keith C Norris
Journal:  Am J Physiol Cell Physiol       Date:  2010-06-30       Impact factor: 4.249

Review 3.  Measures used to treat contrast-induced nephropathy: overview of reviews.

Authors:  C S Kwok; C L Pang; J K Yeong; Y K Loke
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

4.  Efficacy of vitamin E and N-acetylcysteine in the prevention of contrast induced kidney injury in patients with chronic kidney disease: a double blind, randomized controlled trial.

Authors:  Thomas M Kitzler; Aala Jaberi; Gerald Sendlhofer; Peter Rehak; Christian Binder; Eva Petnehazy; Rudolf Stacher; Peter Kotanko
Journal:  Wien Klin Wochenschr       Date:  2012-04-24       Impact factor: 1.704

Review 5.  Contrast-induced acute kidney injury: short- and long-term implications.

Authors:  Steven D Weisbord; Paul M Palevsky
Journal:  Semin Nephrol       Date:  2011-05       Impact factor: 5.299

6.  N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis.

Authors:  Luciana Pache de Faria Guimaraes; Antonio Carlos Seguro; Maria Heloisa Mazzola Shimizu; Letícia Aparecida Lopes Neri; Nairo Massakasu Sumita; Ana Carolina de Bragança; Rildo Aparecido Volpini; Talita Rojas Cunha Sanches; Fernanda Andrade Macaferri da Fonseca; Carlos Alberto Moreira Filho; Maria Helena Vaisbich
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

Review 7.  Contrast-induced nephropathy: pathogenesis and prevention.

Authors:  Robert E Cronin
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

8.  Obesity is not associated with contrast nephropathy.

Authors:  Navin Jaipaul; Rendell Manalo; Seyed-Ali Sadjadi; James McMillan
Journal:  Ther Clin Risk Manag       Date:  2010-05-25       Impact factor: 2.423

9.  Fenoldopam use in a burn intensive care unit: a retrospective study.

Authors:  John W Simmons; Kevin K Chung; Evan M Renz; Christopher E White; Casey L Cotant; Molly A Tilley; Mark O Hardin; John A Jones; Lorne H Blackbourne; Steven E Wolf
Journal:  BMC Anesthesiol       Date:  2010-06-24       Impact factor: 2.217

Review 10.  Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial.

Authors:  Steven D Weisbord; Martin Gallagher; James Kaufman; Alan Cass; Chirag R Parikh; Glenn M Chertow; Kendrick A Shunk; Peter A McCullough; Michael J Fine; Maria K Mor; Robert A Lew; Grant D Huang; Todd A Conner; Mary T Brophy; Joanne Lee; Susan Soliva; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.